Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Luong Tsai"'
Autor:
Ke Peng, Walter Muranyi, Bärbel Glass, Vibor Laketa, Stephen R Yant, Luong Tsai, Tomas Cihlar, Barbara Müller, Hans-Georg Kräusslich
Publikováno v:
eLife, Vol 3 (2014)
The steps from HIV-1 cytoplasmic entry until integration of the reverse transcribed genome are currently enigmatic. They occur in ill-defined reverse-transcription- and pre-integration-complexes (RTC, PIC) with various host and viral proteins implica
Externí odkaz:
https://doaj.org/article/638f67a091d544ddb5e6fdc775e9b331
Autor:
Mini Balakrishnan, Stephen R Yant, Luong Tsai, Christopher O'Sullivan, Rujuta A Bam, Angela Tsai, Anita Niedziela-Majka, Kirsten M Stray, Roman Sakowicz, Tomas Cihlar
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74163 (2013)
HIV-1 integrase (IN) is the target for two classes of antiretrovirals: i) the integrase strand-transfer inhibitors (INSTIs) and ii) the non-catalytic site integrase inhibitors (NCINIs). NCINIs bind at the IN dimer interface and are thought to interfe
Externí odkaz:
https://doaj.org/article/ab7f85858d794836a0e3f22e87f9d8d3
Autor:
Rujuta A. Bam, Luong Tsai, Kirsten M. Stray, Madeleine Willkom, Gabriel Birkus, Tomas Cihlar, Christian R. Frey, Stephen R. Yant
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:316-322
Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV). Previous studies suggested a principal role for the lysosomal serine protease cathepsin A (CatA) in the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e847c93d1018d75dd66f963ec56336
https://doi.org/10.1128/aac.01834-15
https://doi.org/10.1128/aac.01834-15
Autor:
Lianhong Xu, Luong Tsai, Kirsten M. Stray, Barbara Müller, Bärbel Glass, Christian Callebaut, Tomas Cihlar, Hans-Georg Kräusslich
Publikováno v:
Journal of Virology. 87:454-463
GS-8374 is a potent HIV protease inhibitor (PI) with a unique diethyl-phosphonate moiety. Due to a balanced contribution of enthalpic and entropic components to its interaction with the protease (PR) active site, the compound retains activity against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f388dc8519409a1f16968c668985dd6e
https://doi.org/10.1128/jvi.01211-12
https://doi.org/10.1128/jvi.01211-12
Autor:
Lianhong Xu, Tomas Cihlar, Qingyun Yan, Paul W. Hruz, Luong Tsai, Christian Callebaut, Joseph C. Koster
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:1377-1382
Adverse effects induced by HIV protease inhibitors (PIs) are a significant factor in limiting their clinical success. PIs directly contribute to peripheral insulin resistance and alterations in lipid metabolism. GS-8374 is a novel PI with potent anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4290e19937181ac78f3060da18468832
https://doi.org/10.1128/aac.01184-10
https://doi.org/10.1128/aac.01184-10
Autor:
Tomas Cihlar, Bernard P. Murray, William M. Lee, Marcos Hatada, Tina Priskich, Stephanie A. Leavitt, Kirsten M. Stray, Christian Callebaut, Matthew A. Williams, Luong Tsai, Andrew Mulato, Neil Parkin, Lianhong Xu, Kelly Wang, Xiaohong Liu, S. Swaminathan, Carina E. Cannizzaro, Yang Zheng-Yu, Gong-Xin He
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:1366-1376
GS-8374 is a novel bis-tetrahydrofuran HIV-1 protease (PR) inhibitor (PI) with a unique diethylphosphonate moiety. It was selected from a series of analogs containing various di(alkyl)phosphonate substitutions connected via a linker to the para posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4443ec1fa8877324790ffba74bc7184
https://doi.org/10.1128/aac.01183-10
https://doi.org/10.1128/aac.01183-10
Autor:
Luong Tsai, Bärbel Glass, Ke Peng, Hans-Georg Kräusslich, Stephen R. Yant, Barbara Müller, Vibor Laketa, Tomas Cihlar, Walter Muranyi
Publikováno v:
eLife, Vol 3 (2014)
eLife
eLife
The steps from HIV-1 cytoplasmic entry until integration of the reverse transcribed genome are currently enigmatic. They occur in ill-defined reverse-transcription- and pre-integration-complexes (RTC, PIC) with various host and viral proteins implica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c92411433df11ce0d72a959244428e
https://elifesciences.org/articles/04114
https://elifesciences.org/articles/04114
Autor:
Jianhong Wang, Robert G. Strickley, Luong Tsai, Christian Callebaut, Kirsten M. Stray, Bernard P. Murray, Gerry Rhodes, Jennifer K. Chau, Lianhong Xu, Randy Vivian, Manoj C. Desai, You-Chul Choi, Hongtao Liu, Hong Allen Y, S. Swaminathan, Leah Tong, Melody S. Lee
Publikováno v:
Bioorganicmedicinal chemistry letters. 24(3)
The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc987cb1727c9821a454f71a51f3dc1
https://pubmed.ncbi.nlm.nih.gov/24412072
https://pubmed.ncbi.nlm.nih.gov/24412072
Autor:
Melody S. Lee, Hui Hon Chung, Carina E. Cannizzaro, Jennifer K. Chau, Bernard P. Murray, Kirsten M. Stray, Lianhong Xu, Gerry Rhodes, Christian Callebaut, Luong Tsai, Randy Vivian, Manoj C. Desai, You-Chul Choi, Hongtao Liu, Hong Allen Y
Publikováno v:
Bioorganicmedicinal chemistry letters. 24(3)
Ritonavir (RTV), an HIV-1 protease inhibitor (PI), is also a potent mechanism-based inhibitor of human cytochrome P450 3A (CYP3A) and has been widely prescribed as a pharmacoenhancer. As a boosting agent for marketed PIs, it reduces pill burden, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc25fb18290b200b237b897841e6fd4
https://pubmed.ncbi.nlm.nih.gov/24411125
https://pubmed.ncbi.nlm.nih.gov/24411125